These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22089128)

  • 1. Treatment of myocardial dysfunction in sepsis: the Toll-like receptor antagonist approach.
    Kimmoun A; Levy B
    Shock; 2011 Dec; 36(6):633-4. PubMed ID: 22089128
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
    Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
    Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial watch: Sepsis study failure highlights need for trial design rethink.
    Tse MT
    Nat Rev Drug Discov; 2013 May; 12(5):334. PubMed ID: 23629495
    [No Abstract]   [Full Text] [Related]  

  • 4. The search for effective therapy for sepsis: back to the drawing board?
    Angus DC
    JAMA; 2011 Dec; 306(23):2614-5. PubMed ID: 22187284
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 4 modulation as a strategy to treat sepsis.
    Wittebole X; Castanares-Zapatero D; Laterre PF
    Mediators Inflamm; 2010; 2010():568396. PubMed ID: 20396414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid differentiation 2 for treatment of sepsis.
    Duan G; Zhu J; Xu J; Liu Y
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
    Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy.
    Ehrentraut H; Weber C; Ehrentraut S; Schwederski M; Boehm O; Knuefermann P; Meyer R; Baumgarten G
    Eur J Heart Fail; 2011 Jun; 13(6):602-10. PubMed ID: 21613426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the Toll-like receptor 4 antagonist eritoran on retinochoroidal inflammatory damage in a rat model of endotoxin-induced inflammation.
    Ekici F; Karaca EE; Korkmaz S; Yüksel O; Gülbahar Ö; Alper M; Ercan S; Or M
    Mediators Inflamm; 2014; 2014():643525. PubMed ID: 25165412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.
    Liu M; Gu M; Xu D; Lv Q; Zhang W; Wu Y
    Transplant Proc; 2010 Jun; 42(5):1539-44. PubMed ID: 20620471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of eritoran tetrasodium, a toll-like receptor 4 antagonist, on intestinal microcirculation in endotoxemic rats.
    Yeh YC; Ko WJ; Chan KC; Fan SZ; Tsai JC; Cheng YJ; Sun WZ
    Shock; 2012 May; 37(5):556-61. PubMed ID: 22392144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
    Kalil AC; LaRosa SP; Gogate J; Lynn M; Opal SM;
    Shock; 2011 Oct; 36(4):327-31. PubMed ID: 21701421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update.
    Kats S; Schönberger JP; Brands R; Seinen W; van Oeveren W
    Eur J Cardiothorac Surg; 2011 Apr; 39(4):451-8. PubMed ID: 20663682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility.
    Ehrentraut S; Frede S; Stapel H; Mengden T; Grohé C; Fandrey J; Meyer R; Baumgarten G
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2170-6. PubMed ID: 17656666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide.
    Lee YS; Park JS; Jung SM; Kim SD; Kim JH; Lee JY; Jung KC; Mamura M; Lee S; Kim SJ; Bae YS; Park SH
    EMBO Mol Med; 2015 May; 7(5):577-92. PubMed ID: 25766838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental TLR4 inhibition improves intestinal microcirculation in endotoxemic rats.
    Zhou J; Soltow M; Zimmermann K; Pavlovic D; Johnston B; Lehmann C
    Microvasc Res; 2015 Sep; 101():33-7. PubMed ID: 26116862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toll-like receptors, a new way of treatment?].
    Pedersen CV; Østergaard LJ; Mogensen TH; Paludan SR; Bertelsen LS
    Ugeskr Laeger; 2007 Jun; 169(23):2193-8. PubMed ID: 17592684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
    Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
    Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.